WASHINGTON, DC, December 1, 2022 – Everest Clinical Research (“Everest”), a leading full-service contract research organization (“CRO”) with deep expertise in biostatistics and statistical programming, today announced it has acquired Brightech International (“Brightech” or the “Company”).
Founded in 2002, Brightech is a leading CRO that specializes in complex, value-add biostatistics, programming, and clinical data management services. Similar to Everest, Brightech has earned a highly-regarded reputation as a critical partner for some of the world’s largest pharmaceutical and biotech companies. In addition to its New Jersey headquarters, Brightech has an expanded global reach with a second office in Asia. Brightech will continue to be led by Dr. Tai Xie, the Company’s CEO and founder, and the existing management team.
Malcolm Little, a Partner at Arlington Capital Partners, said, “The highly complementary Brightech acquisition is a great start towards accelerating Everest’s inorganic growth. Together, the combined businesses will be better suited to pursue investment opportunities that strengthen existing centers of excellence, add new services, and increase geographic reach. We look forward to supporting Everest’s continued growth through further investments in people, processes, and additional acquisitions.”
Commenting on the announcement, Everest CEO Irene Zhang said, “We are extremely excited to partner with Dr. Xie and his entire team as we continue to expand Everest’s world-class capabilities. Brightech brings with it a highly educated, experienced, and dedicated workforce, including numerous PhDs and Master’s degree holders. With our combined deep bench of biostatistical and clinical data management capabilities, Everest’s broader full-service clinical trial services, and now over 500 employees globally, we will be even better positioned to solve our clients’ most challenging problems.”
Dr. Xie, CEO of Brightech, added, “There is an incredibly strong fit between our two organizations. We both have deeply engrained cultures of innovation, dedication to our customers, and high quality services. We look forward to working together with the Everest team.” He added, “Everest’s scale, resources, and infrastructure will allow us to broaden the scope of our services to existing and future customers while also providing our employees with even more opportunities.”
Bilal Noor, a Principal at Arlington Capital Partners, added, “This investment further expands and diversifies Everest’s blue-chip customer base while also deepening the platform’s core capabilities in fast-growing therapeutic areas such as Oncology, Central Nervous System, and Immunology. We are thrilled to welcome the entire Brightech team into the Everest family and look forward to our successful partnership together.”